Apr19Tue

News from Amicus Therapeutics

News from a former Ambassador Award Honoree: Amicus Therapeutics Announces Issuance of New U.S. Composition of Matter Patent for Galafold® (migalastat), Strengthening Patent Protection Through 2038

Galafold U.S. Intellectual Property Protection Now Includes 35 Issued Patents, 18 of which expire in 2038

PHILADELPHIA, April 19, 2022 (GLOBE NEWSWIRE) — Amicus Therapeutics (Nasdaq: FOLD), a patient-dedicated global biotechnology company focused on developing and commercializing novel medicines for rare diseases, announced today that the United States Patent and Trademark Office (USPTO) has issued U.S. Patent No. 11,304,940, which is directed to a composition of matter covering migalastat (Galafold®).

The new U.S. patent titled “Methods of Treating Fabry Patients Having Renal Impairments” is directed to a molecule comprising migalastat bound to an alpha-galactosidase A protein and expires in 2038.

Read More

Apr13Wed

Member News from Acumen Analytics

Acumen Analytics Launches ‘Life Sphere’ A New Podcast Dedicated to the People in Life Sciences.

The podcast features experts and advocates discussing trends, tools, careers and all components of the Life Sciences industry.

The first episodes of season one will be available May 3. New episodes will be released on Tuesdays. To learn more about Life Sphere, check the Acumen website for more details as they become available https://acumenanalytics.com/news/

Apr08Fri

Board Member News

Irish Chamber Board Member, Eric Karas, is a recognized commercial leader in the biopharmaceutical industry with more than 25 years of sales, marketing, market access, and strategic planning experience across multiple specialty product launches.

Mr. Karas was recently appointed Chief Commercial Officer with ARS Pharma.  Prior he was Vice President & General Manager of Commercial, North America at Emergent BioSolutions. He also led commercial initiatives for NARCAN® Nasal Spray at Adapt Pharmaceutical, which was acquired by Emergent in 2018. Before Adapt Pharmaceutical, Mr. Karas was credited with being at the forefront of Auxilium Pharmaceuticals’ growth during his 8-year tenure and overseeing all global commercial objectives related to its urology portfolio. He also led the launch readiness planning and go-to-market strategy for the launch of XIAFLEX® for Peyronie’s disease. Auxilium was acquired in 2015 by Endo Pharmaceuticals.

Mr. Karas also has held cross-functional roles in government affairs, public relations, patient advocacy, and sales leadership roles at Astellas, Bristol-Myers Squibb, and Merck. Industry associations have also recognized him for numerous disease awareness and branded campaigns targeting HCPs and consumers.

Mr. Karas received his MBA in Integrated Management from Michigan State University, Broad School of Management, and a Bachelor of Science in Accounting from Rutgers University.

Feb22Tue

Thank you to our renewing members!

Thank you to our members who continue to support the Chamber through their membership, you make our mission possible!

Renewing members in February (to date):

Large Corporate Members:
• Dailey LLP,  Jeffery A. Dailey

Mid-Size Firm Members:
• Galera Therapeutics, Mel Sorensen
• The Irish Memorial, John Donovan & Bob Gessler

Individual Members:
• Francis P. McGee, The McGee Group LLC
• Michael Shanahan, Alvarez and Marsal
• Michael O’Rourke, Dortek
• Dianne P. Manges, CFA, Truist Foundations & Endowments Specialty Practice
• Michael Kiernan, Earp Cohn PC
• Roddy Flynn, Office of Congresswoman Mary Gay Scanlon (PA-05)
• Michael Maloney, CBRE